Scripps Research Institute Creates New Drug Discovery Initiative
News Apr 16, 2014
Scripps Advance’s first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.
"Scripps Advance is a truly novel type of relationship designed to combine the diversity and innovation of academic research enterprises with the expertise, infrastructure and capital of the private sector,” said Scott Forrest, Ph.D., TSRI's vice president of business development. “We believe this collaboration structure will prove uniquely effective. Advance will look both inside and outside of TSRI for projects to take forward and it will work with pharma companies to select and fund those projects. Johnson & Johnson Innovation is committed to innovative science, which only raises our level of excitement about Advance.”
Johnson & Johnson Innovation Center in California will tap into Scripps Advance’s strong ties with academic researchers at TSRI, other academic centers and early stage companies to help identify potential collaborators. As part of the relationship, Advance will facilitate match-making between Johnson & Johnson Innovation and emerging life science companies, companies-in-planning, researchers conducting translational research and entrepreneurs that are part of Scripps Advance’s network.
Scripps Advance has already been active in the biotech space, collaborating with Atlas Venture, an early stage investment firm, to launch a company called Padlock Therapeutics. Padlock discovers novel therapeutics targeting the protein arginine deiminases (PADs), an emerging class of enzymes with roles in autoimmunity and epigenetic control. Padlock’s technology was developed in the laboratories of TSRI investigators Paul Thompson, Ph.D., and Kerri Mowen, Ph.D., in collaboration with the Scripps Florida’s high-throughput screening facility.
Todd Huffman, Ph.D., TSRI’s director of drug discovery partnerships, said, “In building Scripps Advance we recognized the need to focus on therapeutic developments with the potential to lead to game changing ways in which we treat disease. The expertise and technical breadth found at our Florida site has already had a significant impact on putting drug candidates into the clinic. We look forward to broadening our footprint in this area through collaborations with Johnson & Johnson Innovation and other companies.”
Fermentation Byproduct Suppresses Seizures in Nerve Agent PoisoningNews
A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018